New York, June 23 EST: What began as a splashy partnership in April is now a full-blown public split. On Monday, Novo Nordisk terminated its deal with Hims & Hers, accusing the telehealth company of marketing unauthorized, compounded versions of semaglutide—the core ingredient in its flagship weight-loss drug, Wegovy.
The fallout was immediate. Hims & Hers stock cratered over 30%, its worst trading day since listing. Novo shares dropped too, albeit less dramatically—down about 5–6%—as investors reassessed the drugmaker’s digital strategy and its capacity to protect market exclusivity.
The Legal Line Just Shifted
The backdrop here is critical. The FDA recently removed semaglutide from its drug shortage list, a move that effectively shut down the legal rationale for compounded versions of the drug. Pharmacies and DTC platforms like Hims & Hers that had been offering lower-cost, personalized formulations suddenly found themselves on thinner ice.
Novo acted quickly. In its statement, the company accused Hims of blurring the line between individualized medicine and mass-market compounding—offering versions of semaglutide it says are “non-compliant,” “potentially unsafe,” and sourced from non-FDA-regulated Chinese suppliers. It was less a warning shot than a cease-and-desist with press coverage.
Hims Says It’s a Power Play
Hims & Hers CEO Andrew Dudum wasted no time in firing back. He called Novo’s move “misleading and anticompetitive,” arguing the company is trying to box out cost-effective alternatives to Wegovy and force patients into its own branded supply chain.
Dudum defended Hims’ compounded offerings—priced around $165/month, well below Wegovy’s sticker price—as medically justified and legally permissible under the FDA’s rules prior to the recent shortage update. He made it clear the company doesn’t plan to back down from GLP-1 offerings, even without Novo’s backing.
But from a risk perspective, the loss is a significant one. The Novo deal gave Hims a degree of brand legitimacy in a highly regulated space. Without it, the company is back in the gray zone—fighting for consumer trust, regulatory clarity, and competitive footing in a booming weight-loss drug market now under tighter scrutiny.
The Bigger Issue: Control of Distribution
At its core, this isn’t about a few misbranded doses—it’s about control of distribution channels in a market moving at biotech speeds but under pharmacy law. Novo is pushing hard to limit access to its GLP-1 franchise to fully FDA-compliant platforms, like Ro and LifeMD, which have agreed to play by the rules. That includes using branded Wegovy, sourcing only through certified U.S. pharmacies, and following strict dosing protocols.
Hims, by contrast, had been building a model around compounded alternatives—arguably legal until recently but now on shakier footing. With the shortage designation gone, regulators are likely to step up enforcement, and pharmacies skirting the boundary could face audits or worse.
Why Investors Are Nervous
For Hims, the downside is immediate: fewer prescriptions, higher legal exposure, and reputational risk in a category where consumer trust is everything. For Novo, the split is less financially material—Hims wasn’t a major sales channel—but it raises bigger questions about how aggressively the company can police its pipeline as competitors like Eli Lilly’s Zepbound gain share.
Analysts have flagged this episode as a sign of growing regulatory risk in the direct-to-consumer pharma model, especially in categories with sky-high demand and tight supply chains. GLP-1s aren’t like vitamins or skincare—the legal landscape is tougher, and the players more litigious.
If anything, the fight between Novo and Hims signals a broader shift: the next phase of growth in consumer health won’t be about flashy partnerships or volume—it’ll be about compliance, supply discipline, and brand control.
New Jersey Times Is Your Source: The Latest In Politics, Entertainment, Business, Breaking News, And Other News. Please Follow Us On Facebook, Instagram, And Twitter To Receive Instantaneous Updates. Also Do Checkout Our Telegram Channel @Njtdotcom For Latest Updates.
A Wall Street veteran turned investigative journalist, Marcus brings over two decades of financial insight into boardrooms, IPOs, corporate chess games, and economic undercurrents. Known for asking uncomfortable questions in comfortable suits.
